Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab--a novel, patient-tailored monoclonal antibody therapy--showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped, Mount Sinai researchers reported in The Lancet.
\
\
